Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Global R&D Center names new president
As president of Takeda Global R&D, Center, US, Dr Nabulsi directs all aspects of Takeda’s US drug development activities, including the identification of new product candidates, execution of
As president of Takeda Global R&D, Center, US, Dr Nabulsi directs all aspects of Takeda’s US drug development activities, including the identification of new product candidates, execution of
The agreement gives Svelte Medical exclusive rights to some intellectual property related to ‘stent-on-a-wire’ delivery systems as well as non-exclusive rights to several stent designs for use on
The primary objective of this open-label study is to assess the functionality of the ARX-01 system for post-operative pain management in patients undergoing unilateral knee replacement surgery. Thomas
The entire complement of Alsius products will continue to be offered by Zoll to meet the ongoing needs of Alsius customers and their patients. This includes both the
The orphan drug designation is granted for the prevention of arteriovenous fistula or arteriovenous graft failure in patients with end-stage renal disease receiving hemodialysis or preparing for hemodialysis.
According to Integra LifeSciences, Coral extended tab spinal screws are designed for applications where the extent of the vertebral misalignment would not allow a standard sized tab pedicle
The company currently has agreements with 60 investigational sites in the US for Phase III trials of NX-1207, and expects the number of clinical trial sites to be
The company has recently announced results from its Phase II study and intends to initiate a Phase III clinical program in this indication in the second half of
This Phase IIb trial is an important milestone for Oramed as it will test its first indication for ORMD-0801 on a large group of volunteers for the duration
Under the terms of the agreement Sigmar will pay Stellar an upfront licensee fee, plus a specified transfer price in exchange for the rights to an exclusive license